{
    "Trade/Device Name(s)": [
        "MicroScan\u00ae Synergies plus\u2122 Gram-Positive MIC/Combo Panels",
        "MicroScan\u00ae Synergies plus\u2122 Gram-Positive MIC/Combo Panels with Trimethoprim/Sulfamethoxazole"
    ],
    "Submitter Information": "Dade Behring Inc.",
    "510(k) Number": "K051350",
    "Predicate Device Reference 510(k) Number(s)": [],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "LON",
        "JWY",
        "LRG",
        "LTT"
    ],
    "Summary Letter Date": "July 25, 2005",
    "Summary Letter Received Date": "June 1, 2005",
    "Submission Date": "May 19, 2005",
    "Regulation Number(s)": [
        "21 CFR 866.1645",
        "21 CFR 866.1640"
    ],
    "Regulation Name(s)": [
        "Fully automated short-term incubation cycle antimicrobial susceptibility system"
    ],
    "Analyte Class(es)": [
        "microbiology"
    ],
    "Analyte(s)": [
        "Trimethoprim/Sulfamethoxazole"
    ],
    "Specimen Type(s)": [
        "Colonies grown on solid media of rapidly growing aerobic and facultative anaerobic gram-positive staphylococci and enterococci"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "WalkAway\u00ae SI System",
        "MicroScan\u00ae Instrumentation",
        "Equivalent instruments"
    ],
    "Method(s)/Technology(ies)": [
        "Microdilution antimicrobial susceptibility testing",
        "Rapid fluorogenic identification",
        "Dried overnight AST technologies"
    ],
    "Methodologies": [
        "Quantitative antimicrobial susceptibility testing",
        "Qualitative antimicrobial susceptibility testing"
    ],
    "Submission Type(s)": [
        "Panel",
        "System",
        "Reagent"
    ],
    "Document Summary": "FDA 510(k) summary for MicroScan Synergies plus Gram-Positive MIC/Combo Panels with addition of Trimethoprim/Sulfamethoxazole for antimicrobial susceptibility testing.",
    "Indications for Use Summary": "Used to determine quantitative and/or qualitative antimicrobial agent susceptibility of colonies of rapidly growing aerobic and facultative anaerobic gram-positive staphylococci and enterococci; this submission adds Trimethoprim/Sulfamethoxazole to the panel.",
    "fda_folder": "Microbiology"
}